Actions by Novo, Ozempic and Wegovy, Fall Back in the Midst of Questions From Analysts About Precision and M&A – Money Times
3 Articles
3 Articles
On Monday's Capital Markets Day, Mike Doustdar himself highlighted the "elephant in the room", but if you ask two analysts, it was just one of several topics that the market wanted answers to.
Novo CEO Mike Doustdar will answer a number of questions from analysts and investors on Monday. This will take place at the company's Capital Markets Day, where Novo's future portfolio of drugs will once again be high on the agenda, analysts estimate.
Novo Nordisk's actions retreated on Monday, while executives faced difficult questions from analysts about the power of pharmaceutical precision and its strategy of mergers and acquisitions, faced with the proximity of the expiration of important patents. Novo intends to launch more than five highly successful drugs by 2030 and generate more than 150 [...]
Coverage Details
Bias Distribution
- 100% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
